<DOC>
	<DOCNO>NCT00583128</DOCNO>
	<brief_summary>The objective study evaluate safety effectiveness experimental drug AST-120 treating patient non-constipating IBS . The study test whether patient receive AST-120 experience least 50 % reduction number day abdominal pain compare placebo .</brief_summary>
	<brief_title>Safety Efficacy AST-120 Patients With Non-Constipating Irritable Bowel Syndrome</brief_title>
	<detailed_description>Patients experience non-constipating IBS randomize one two arm study : experimental drug AST-120 placebo . Patients take 2g AST-120 placebo three time per day eight week . After 8 week course , patient receive additional 8 week single blind treatment , one week washout period . The experimental drug AST-120 compose black , odorless spherical carbon particles 2g sachet ( aluminum foil pouch ) . The placebo consist microcrystalline cellulose sphere , Celphere CP-305 stain match appearance AST-120 , 2g sachet ( aluminum foil pouch ) . Both AST-120 placebo oral ( take mouth ) preparation . Both tasteless . To take product , patient tear open sachet , drop content directly tongue wash 8 ounce water . Patients expect participate 10 visit , approximately three telephone remainder visit in-clinic . At visit , patient undergo number test include : hematology panel , lactose intolerance testing , physical exam , pregnancy test , evaluation base follow scale : The Bristol Stool Scale , IBS Severity Scale , IBS Quality Life , SCL-90R . Provided patient stable eight week prior baseline visit , allow take follow medication : drug inhibit gastric secretion ( histamine blocker , proton pump inhibitor ) , benzodiazepine Imidazopyridines ( short acting , nonbenzodiazepine hypnotic ) sleep ( dose must consistent use sleep agent ) aspirin cardiovascular prophylactic dose ( 75-150 mg/day ) paracetamol . Antidepressants non-IBS symptom allow . Loperamide permit rescue diarrhea patient experience least 3 liquid soft stool one day . However , Loperamide prohibit two week screen period . Patients allow take follow medication whilst trial therapy must discontinue least two week prior baseline visit : probiotic , neuroleptic , antidepressant IBS symptom , daytime tranquilizer , prokinetics , spasmolytic , analgesic , investigational agent over-the-counter medication . Patient required keep diary study</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Body weight ≥ 40 kg ; Recurrent abdominal pain discomfort three day per month last three month meet Rome III criterion nonconstipating IBS ; Patients stable diet least eight week ; Patients ≥ 50 year age negative screening colonoscopy last five year ; Able willing comply protocol procedure plan duration study ; Able willing understand , sign date inform consent document , authorize access protect health information , Females must postmenopausal , surgically incapable bearing child , practice reliable method birth control ( intrauterine device , spermicide barrier ) ( Hormonal contraceptives NOT regarded adequate purpose trial . ) Partner/spouse sterility may also qualify Investigator 's discretion . Females childbearing potential must negative urine pregnancy test baseline . Constipating IBS ; History untreated lactose intolerance ; History colonic major abdominal surgery ( colectomy , example ) ; Active ( untreated ) Thyroid disease ; Current diagnosis major depression psychosis ; Known positive stool culture Clostridium difficile pathogen ; Any condition necessitate administration analgesic ( except paracetamol ) , probiotic , neuroleptic , antidepressant IBS symptom , daytime tranquilizer , prokinetics spasmolytic medication ; Poor tolerability venipuncture lack adequate venous access require blood sampling ; Other major physical major psychiatric illness within last six month opinion investigator would affect patient 's ability complete trial ; Uncontrolled systemic disease diabetes ; Patients undergo chemotherapy treatment cancer ; Known hypersensitivity contraindication component test product ( study drug ) diagnostics use ; Participation another study within eight ( 8 ) week prior study ; Unable attend visit require protocol ; Female patient must exclude pregnant , breast feeding , plan become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>IBS</keyword>
	<keyword>Irritable Bowel Syndrome</keyword>
</DOC>